

# International Prescription Drug Price Comparisons

United States + 32 OECD Nations, 2018

U.S. = 100

The 2018 prescription drug market totalled sales of \$795.2 billion and volume of 1,016.2 billion standard units.

The United States accounted for 58% of sales but only 24% of volume. Japan, by comparison, accounted for 9% of sales and 21% of volume.

Brand-name drugs accounted for 11% of U.S. drug volume and 82% of spend.

U.S. prices were 256% of those in the 32 OECD comparison countries combined.

In comparisons with individual countries, U.S. prices ranged from 170 percent of prices in Mexico to 779 percent of prices in Turkey.

The analysis used manufacturer prices for drugs because net prices - the prices ultimately paid for drugs after negotiated rebates and other discounts are applied - are not systematically available.

However, even after adjusting prices downward to account for rebates and other discounts, U.S. prices were 190 percent of prices in other countries

Analysis based on IQVIA's MIDAS data set (run date October 28, 2019).

